Samsara BioCapital — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Nkarta, Inc.NASDAQ: NKTXAug 2019
Developing allogeneic or off-the-shelf cell therapies for cancer and auto-immune disease based on Natural Killer cells.
South San Francisco, US
Board seatMichael Dybbs· per SEC Form D
Chinook Therapeutics U.SFeb 2019SEC filingmedium confidence
Seattle, US
Sam Hall(Director)Eric Dobmeier(Executive Officer, Director)
BoardJeremy Caldwell(Director)Jerel Davis(Director)
Board seatSrinivas AkkarajuSrini Akkaraju· per SEC Form D · $115M raise · filed Oct 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.